Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 11/20 | 0.64 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.50 |
| ▸ | THRA | P10827 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27360541 | 0.91 | PLA2G2A (0.79) | PLA2G2A | |
| SCHEMBL27407027 | 0.89 | PLA2G2A (0.59) | PLA2G2APLA2G1BGAAMAPTPKM | |
| SCHEMBL5437216 | 0.88 | PLA2G2A (0.82) | PLA2G2APLA2G1BGAAMAPTPKM | |
| SCHEMBL27389295 | 0.88 | PLA2G2A (0.67) | PLA2G2AGAAMAPTPKMALDH1A1 | |
| SCHEMBL2004123 | 0.83 | PLA2G2A (0.71) | PLA2G2APLA2G1BGAAMAPTPKM | |
| SCHEMBL27359914 | 0.81 | PLA2G2A (0.50) | PLA2G2APLA2G1BMAPTPTGDR2THRA | |
| SCHEMBL2004243 | 0.81 | PLA2G2A (0.72) | PLA2G2APLA2G1BGAAMAPTPKM | |
| SCHEMBL27452759 | 0.81 | PLA2G2A (0.79) | PLA2G2A | |
| SCHEMBL11254007 | 0.80 | PLA2G2A (0.54) | PLA2G2AGAAMAPTPKMALDH1A1 | |
| SCHEMBL2010470 | 0.80 | PLA2G2A (0.63) | PLA2G2APLA2G1BGAAMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8884020-B2 | Indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8884020-B2 | Indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2610244-A1 | Indole compounds | Ironwood Pharmaceuticals, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-7960544-B2 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960544-B2 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960544-B2 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100197708-A1 | INDOLE COMPOUNDS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2010-08-05 | — | — | US | disclosed |
| US-20100197708-A1 | INDOLE COMPOUNDS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2010-08-05 | — | — | US | disclosed |
| US-20090264653-A1 | USEFUL INDOLE COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264653-A1 | USEFUL INDOLE COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| CN-1068588-C | 1H-indole-3-acetamide splA2 inhibitors | LILLY CO ELI (US) | 2001-07-18 | — | — | CN | disclosed |
| CN-1067986-C | 1H-indole-3-acetic acid hydrazide spla2 inhibitors | LILLY CO ELI (US) | 2001-07-04 | — | — | CN | disclosed |
| CN-1098714-A | The 1H-indole-3-acetic acid hydrazide spla 2 inhibitors | LILLY CO ELI (US) | 1995-02-15 | — | — | CN | disclosed |
| CN-1098715-A | PLA 2 inhibitors 1H-indole-3-acetamide compounds | LILLY CO ELI (US) | 1995-02-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197708-A1 | INDOLE COMPOUNDS | IDO1, IDO2, TPH2 | PLA2G2A 3285/4885PLA2G1B 2354/4885GAA 4587/4885 |
| US-20090264653-A1 | USEFUL INDOLE COMPOUNDS | FAAH, FAAH2, AANAT | PLA2G2A 326/4885PLA2G1B 220/4885GAA 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.